Navigation Links
Intellect Neurosciences, Inc. Validates Pivotal European Patent for Alzheimer's Monoclonal Antibody Platform
Date:11/11/2008

ia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits known as beta-amyloid on the surface of nerve cells, which results from the accumulation of soluble beta-amyloid in the brain. The effects of the disease are devastating to the patients as well as the caregivers, with significant associated health care costs. It is estimated that there are more than 5 million Americans and about 30 million people suffering from Alzheimer's disease world wide with the number expected to increases dramatically as the global population ages. Currently marketed drugs transiently affect some of the symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. These symptomatic drugs are projected to generate more than $6 billion in sales by 2010, indicating both the size of the market and the demand for effective treatment beyond symptomatic improvements.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of AD and other disorders. The Company has a broad proprietary immunotherapy platform for both passive and active immunization against AD. Also, Intellect has completed Phase I clinical trials for OXIGON(TM), which has the potential to be used as a treatment for AD and other serious disorders.

For additional information, please visit http://www.intellectns.com

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including without limitation those regarding future performance or financi
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Depression can foreshadow intellectual decline in older people
2. Therap Services to Attend 2nd International Conference on Intellectual Disabilities/Mental Retardation as Gold Sponsor
3. Written Statement of Kevin J. OConnor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement
4. StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform
5. Allarae Healthcare Inc. Announces Signing of Distribution Agreement With Intellect Inc.
6. John Josef Molenda Joins Firms Intellectual Property Practice as Of Counsel
7. Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
8. CJPS Enterprises Spins Off New Company for Intellectual Property Marketing
9. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
10. Mutant gene causes epilepsy, intellectual disability in women
11. Intellectual Property Buildup Seminar to be Held in Detroit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Today The FSH Society, a world leader in ... Song,” featuring luminary pianist Steven Blier and two-time Grammy Award ... 2014 at the Tappan Hill Mansion, located on the former ... is proud to welcome Blier, who performs each year, and ... research. , FSHD, one of the most prevalent types of ...
(Date:9/16/2014)... Norfolk, VA (September 16, 2014) – ... desserts, announced today the launch of a limited edition ... October. In support of the American Cancer Society, an ... charitable donation in 2014 as well as help to ... among women in the United States. , The ...
(Date:9/16/2014)... 2014 (HealthDay News) -- Key connections between brain ... people with attention deficit hyperactivity disorder (ADHD), according ... within and between certain brain networks control ... the ability to focus on external tasks. This ... light on why those with ADHD are easily ...
(Date:9/16/2014)... 16, 2014 After working together for eight ... the premier fertility centers in the late 1990s and early ... to their hometown of New York City to launch Chelsea ... Genetics Labs. , Chelsea Fertility NYC offers full service ... in the New York Tri-State Area, and provides equal access ...
(Date:9/16/2014)... Dr. Randy Carlson and The Intentional Living ... Marriage event is coming to the Phoenix and Tucson ... better communicate, increase intimacy and have more fun with their ... and learning to strengthen your marriage and to rediscover intimacy,” ... Bible Church (Mesa), Saturday, Sept. 27 – Glendale Church of ...
Breaking Medicine News(10 mins):Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 2Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 3Health News:Lucy’s Joins Fight Against Breast Cancer With Launch Of Limited Edition Packaging And Charitable Donation 2Health News:Lucy’s Joins Fight Against Breast Cancer With Launch Of Limited Edition Packaging And Charitable Donation 3Health News:Study Sees Differences in Brain Connections of Kids With ADHD 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 4Health News:The Intentional Living Center Introduces the Love Your Marriage Night Featuring Dr. Randy Carlson in Arizona 2
... data is showing a dramatic,reduction in the accidental ... more on one group,s 20-year effort to protect ... from Safe Kids Worldwide at:, http://media.medialink.com/WebNR.aspx?story=35058 , ... and,photos for free and unrestricted use at ...
... Brown & Toland Medical Group,today announced a strong financial ... on total revenues of $235 million., The medical ... performance and other related bonuses from health plans. The,medical ... $8.2,million in bonus payments to eligible physicians. In 2007 ...
... seem to cause drop in heart rate variability, researchers ... of a small study show that the electromagnetic field ... babies, Italian researchers report. , Whether these changes in ... could have implications for premature infants who can spend ...
... the Only Treatment Approved to Both Reduce Exacerbations ... ... 30 The,U.S. Food and Drug Administration today approved Advair ... powder),for the reduction of exacerbations in patients with chronic obstructive,pulmonary ...
... better way to distinguish acute leukemia patients who require aggressive ... therapy for cure., The study is published in the May ... an accompanying editorial. , Researchers say that changes in levels ... the kinds and amount of proteins they make, might predict ...
... April 30 Allscripts, the leading,provider of clinical ... improve healthcare, today announced results for the three,months ... ), Total revenue for the three months ... $65.0 million for the same period last year,increasing ...
Cached Medicine News:Health News:Brown & Toland Announces 2007 Financial Results 2Health News:Incubators Affect Newborns' Heart Rates 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 3Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 4Health News:Molecular change may reveal risk of leukemia relapse 2Health News:Molecular change may reveal risk of leukemia relapse 3Health News:Allscripts Reports First Quarter 2008 Results 2Health News:Allscripts Reports First Quarter 2008 Results 3Health News:Allscripts Reports First Quarter 2008 Results 4Health News:Allscripts Reports First Quarter 2008 Results 5Health News:Allscripts Reports First Quarter 2008 Results 6Health News:Allscripts Reports First Quarter 2008 Results 7Health News:Allscripts Reports First Quarter 2008 Results 8Health News:Allscripts Reports First Quarter 2008 Results 9Health News:Allscripts Reports First Quarter 2008 Results 10
(Date:9/15/2014)... 2014 /CNW/ - Health Minister Rona Ambrose today ... for donation over $2.5 million in personal protective equipment (PPE) ... global response to the Ebola outbreak in West ... shortage of equipment in the affected countries and has appealed ... in the affected countries. Personal protective equipment ...
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire/ -  Pivotal Therapeutics ... specialty pharmaceutical company with a focus on Omega-3 ... today that the Board of Directors approved the ... an advisor at the close of business on Friday, ... of 1,000,000 common shares of the Company were ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- ... affects persons of all ages, but most commonly ... condition characterized by narrowing of the airways, leading ... the lungs come into contact with endogenous and ... of events, such as swelling of the airways, ...
Breaking Medicine Technology:Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 2Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 3Pivotal Therapeutics Grants Incentive Stock Options 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5
... VIVUS, Inc. (Nasdaq: VVUS ) announced today ... the U.S. Food and Drug Administration (FDA) regarding its ... QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL ... approved in its present form.  The application seeks the ...
... Corporation (Nasdaq: THOR ), a world leader ... and restore failing hearts, said revenues from continuing operations ... versus the third quarter of 2009. Results ... first nine months of 2010 and 2009 exclude contributions ...
Cached Medicine Technology:FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 2FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 4FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 2Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 3Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 4Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 6Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 7Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 8Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 9Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 10Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 11Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 12Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 13Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 14Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 15Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 16
Inquire...
... Roches patented polymerase chain reaction (PCR) ... technology, is an essential component of Roches ... PCR allows minute amounts of selected unique ... into billions of copies (that is, to ...
... Introducing BenchMark XT® the only fully ... flexibility you need to expand your ... improve your slide turnaround time. All ... choose how to use the BenchMark ...
... Reicherts new ATP Auto Non-Contact Tonometer / ... / pachymeter, combining the measurement of IOP ... response to numerous clinical studies that have ... thickness as well as intraocular pressure in ...
Medicine Products: